Pfizer ventures into stem cell treatments for eye diseases

06/23/2008 | Forbes · Boston Globe (tiered subscription model), The

Pfizer will provide $3 million to finance the creation of EyeCyte, a stem cell research and development company that will focus on ophthalmic disorders such as diabetic retinopathy. Under the agreement, Pfizer has the right of first refusal to acquire the company or its technologies if the treatment proves successful within the next few years.

View Full Article in:

Forbes · Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care